Atonomics announces important milestone in Troponin I assay on new Atolyzer system

Published on November 26, 2012 at 9:59 AM · No Comments

Atonomics A/S announced today that it has achieved an important milestone related to a defined set of performance criteria for a Troponin I assay on the new Atolyzer® system.

Since entering an equity investment agreement with Beckman Coulter in May of last year to advance the Atolyzer® within cardiac testing, the company has worked diligently to deliver relevant Troponin I performance data.

"We are pleased to achieve this milestone," said Thomas Warthoe, Atonomics' CEO. "Troponin I is one of the most difficult assays to transfer to a near-patient system and still deliver data that are comparable to what the physicians get from the central laboratory; we believe the Atolyzer® has the potential to allow physicians in the future to continue to safely implement data from a near patient system."

"We expect that this recent and significant achievement will generate appropriate interest from Industry in order to reach the full potential of the Atolyzer® platform," said Ashok Dhanrajgir, Chairman of Atonomics board of directors and senior partner with Inventages Venture Capital

Atonomics' majority shareholders are Inventages Venture Capital, Sunstone Capital, NeuroSearch A/S,  and Beckman Coulter.

 

 

Source:

Atonomics A/S

Posted in: Device / Technology News

Tags: ,

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
The future of high throughput screening: an interview with Mark Wigglesworth, Director High Throughput Screening, AstraZeneca